A recent study suggests that patients who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise programs.
Findings released in a leading health publication shows that while overweight individuals often shed substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"People using these medications must be informed of the danger of quick weight regain when the medication is stopped," warns expert Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight in about 18 months.
Weighing Approaches
The analysis, which looked at dozens of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with other pills.
The team emphasize that people who shed pounds through diet and exercise usually experience a more gradual creep back—perhaps 100 grams monthly—after stopping.
Understanding the Fast Regain
Nutrition scientists suggest the mechanism of the jabs is key to understanding the accelerated regain.
The injections mimic a body's own chemical called GLP-1, which controls appetite.
"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines advise the jabs for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals contend that, due to the high risk of relapse, the treatment is often long-term.
This view is supported by pharmaceutical companies, who state that the results "highlight the chronic nature of obesity," similar to managing conditions like hypertension.
User Testimonies
Individuals who have discontinued the jabs explain a intense return of appetite.
"It felt as if a switch activating and you become extremely hungry," described an individual.
This difficulty is exacerbated if individuals have not adopted sustainable dietary or behavioural modifications during therapy.
Significant Interest
Survey data indicate that millions of adults in the UK have used these injections in the past year, with demand continuing to grow.
- Adoption is higher among women than males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, experts stress that while GLP-1 drugs are potent agents for weight loss, they are not a standalone solution and maintained weight loss relies on ongoing behavioural changes.
